Lead Product(s) : NNC6019
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Novo Nordisk
Deal Size : $1,200.0 million
Deal Type : Acquisition
Details : PRX004 is an investigational humanised monoclonal antibody designed to deplete amyloid associated with disease pathology that underlies hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein.
Product Name : NNC6019
Product Type : Antibody
Upfront Cash : $100.0 million
November 21, 2022
Lead Product(s) : NNC6019
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Novo Nordisk
Deal Size : $1,200.0 million
Deal Type : Acquisition
Lead Product(s) : Epeleuton
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TRIAGE is a dose finding Phase IIb study being conducted in Germany, Israel, Latvia, Switzerland and the United States to assess the efficacy and safety of orally administered epeleuton in 240 patients with hypertriglyceridemia and type 2 diabetes.
Product Name : DS102
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 23, 2020
Lead Product(s) : Epeleuton
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable